secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001711279-25-000069
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study
--------------------------------------------------------------------------------

- PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.
- 81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.
- Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.
- Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.
- KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/0001711279-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/krys-20250724.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer